CIM
RIGL icon

Cambria Investment Management’s Rigel Pharmaceuticals RIGL Stock Holding History

Cambria Investment Management’s Portfolio RIGL Stock Details RIGL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q3 		– Sell
-254
Closed -$8K – 358
2015
Q2 		$8K Buy
+254
New +$9.7K ﹤0.01% 263

Other funds holding RIGL

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
O
OppenheimerFunds New York $80.4B AUM 15.1% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Cambria Investment Management's RIGL Position: Q3 2015 in Review

Cambria Investment Management sold out of Rigel Pharmaceuticals (RIGL) in Q3 2015, closing a stake of 254 shares — an estimated $8K sold.

Cambria Investment Management first reported a position in RIGL in Q2 2015 and held it in 1 quarter. The position peaked at $8K in Q2 2015. 122 funds tracked by Wall St. Rank hold RIGL as of Q3 2015.

  • Cambria Investment Management reported no remaining Rigel Pharmaceuticals position as of Q3 2015 after selling out during the quarter.
  • Cambria Investment Management sold 254 Rigel Pharmaceuticals shares in Q3 2015, an estimated $8K.
  • Cambria Investment Management first reported a position in Rigel Pharmaceuticals in Q2 2015 and held it in 1 quarter.
  • Cambria Investment Management's Rigel Pharmaceuticals position peaked at $8K in Q2 2015.
  • 122 funds tracked by Wall St. Rank held Rigel Pharmaceuticals as of Q3 2015.

Based on Cambria Investment Management's 13F filing for Q3 2015, filed 2 Nov 2015.